This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026
We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations. 3
What this version reported
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.↗
Organizations named in cited records:
- Stealth BioTherapeutics Inc.↗
Trial records: NCT07531251
Sources for this version
- 14TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Forzinity (elamipretide): NDA 215244 accelerated approval letter, September 19, 2025 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 3FORZINITY, revised September 2025: U.S. prescribing information ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026